Abstract:Atorvastatin is a classical lipid-lowering drug. It has been reported to have renoprotective effects, such as reducing urinary protein excretion and extracellular matrix aggregation. The present study aimed to investigate the specific mechanism of action of Atorvastatin in type 1 diabetic mice (T1DM) in inhibiting renal tubular epithelial cell injury following treatment with high glucose and high fat. The anti-injury mechanism of Atorvastatin involved the inhibition of miR-21 expression and the upregulation of the transcription and expression of its downstream gene Peroxisome proliferator-activated receptors-α(PPARα). An increase in blood glucose and lipid levels was noted in the T1DM model, which was associated with renal fibrosis and inflammation. These changes were accompanied by increased miR-21 levels, downregulation of PPARα and Mfn1 expressions, and upregulation of Drp1 and IL6 expressions in renal tissues. These phenomena were reversed following the administration of Atorvastatin. miR-21 targeted PPARα by inhibiting its mRNA translation. Inhibition of miR-21 expression or Fenofibrate (PPARα agonist) administration prevented the decrease of PPARα in renal tubular epithelial cells under high glucose (HG) and high fat (Palmitic acid, PA) conditions, alleviating lipid metabolism disorders and reducing mitochondrial dynamics and inflammation. Consistent with the in vivo results, the in vitro findings also demonstrated that mRTECs administered with Atorvastatin in HG + PA increased PPARα expression and restored the normal expression of Mfn1 and Drp1, and effectively increasing the number of biologically active mitochondria and ATP content, reducing ROS production, and restoring mitochondrial membrane potential following Atorvastatin intervention. In addition, these effects were noted to the inhibition of FN expression and tubular cell inflammatory response; however, in the presence of miR-21mimics, the aforementioned effects of Atorvastatin were significantly diminished. Based on these observations, we conclude that Atorvastatin inhibits tubular epithelial cell injury in T1DM with concomitant induction of lipid metabolism disorders by a mechanism involving inhibition of miR-21 expression and consequent upregulation of PPARα expression. Moreover, Atorvastatin regulated lipid metabolism homeostasis and PPARα to restore mitochondrial function. The results emphasize the potential of Atorvastatin to exhibit lipid-regulating functions and non-lipid effects that balance mitochondrial dynamics.

Atorvastatin Restores PPARα Inhibition of Lipid Metabolism Disorders by Downregulating miR-21 Expression to Improve Mitochondrial Function and Alleviate Diabetic Nephropathy Progression

Atorvastatin Improves Cardiac Lipid Metabolism in Spontaneous Hypertensive Rats and Ameliorates Cardiac Hypertrophy

The Effect of Atorvastatin on Lowering Lipids in Elderly Patients with Type 2 Diabetic Mellitus Plus Hyperlipidemia

Tissue-specific Effects of Atorvastatin on 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Expression and Activity in Spontaneously Hypertensive Rats

Atorvastatin exerts inhibitory effect on endothelial senescence in hyperlipidemic rats through a mechanism involving down-regulation of miR-21-5p/203a-3p

Atorvastatin Targets the Islet Mevalonate Pathway to Dysregulate Mtor Signaling and Reduce Β-Cell Functional Mass

Atorvastatin ameliorates diabetic nephropathy through inhibiting oxidative stress and ferroptosis signaling.

Atorvastatin ameliorated myocardial fibrosis in db/db mice by inhibiting oxidative stress and modulating macrophage polarization

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy

Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products.

Effect of atorvastatin on NF-κB in peripheral blood mononuclear cells and renal tissues in diabetic rats

Atorvastatin Regulates MALAT1/miR-200c/NRF2 Activity to Protect Against Podocyte Pyroptosis Induced by High Glucose.

Atorvastatin Blocks Advanced Glycation End Products Induced Reduction in Macrophage Cholesterol Efflux Mediated with ATP-Binding Cassette Transporters G 1

Atorvastatin Ameliorates Lipid Overload-Induced Mitochondrial Dysfunction and Myocardial Hypertrophy by Decreasing Fatty Acid Oxidation Through Inactivation of the P-Stat3/cpt1 Pathway.

Pioglitazone Ameliorates Atorvastatin-Induced Islet Cell Dysfunction Through Activation of FFA1 in INS-1 Cells

Atorvastatin Alleviates Experimental Diabetic Cardiomyopathy by Regulating the GSK-3β-PP2Ac-NF-κB Signaling Axis.

Atorvastatin Inhibits Inflammation in Experimental Diabetes Mellitus Rats

Effect of Atorvastatin on the Expression of Integrin α_3β_1 in the Kidney of Diabetic Rats

Microrna-22 Downregulation by Atorvastatin in A Mouse Model of Cardiac Hypertrophy: A New Mechanism for Antihypertrophic Intervention

Atorvastatin Improves Plaque Stability in Diabetic Atherosclerosis Through the RAGE Pathway.